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http://dxObjective: Nonocclusive mesenteric ischemia (NOMI) may occur after cardiopulmonary bypass. It is crucial to
early identify patients who are at risk of developing this complication. The aim of this prospective study was to
evaluate perioperative risk factors in a large cohort of patients undergoing elective cardiac surgery.
Methods: From January 1, 2010, to March 31, 2011, all patients scheduled for elective cardiac surgery were
screened for participation in this trial. If NOMI was suspected, arterial angiography was performed. NOMI
and non-NOMI patients were compared with respect to all variables assessed in this study. Additionally, odds
ratios were calculated. Linear discriminant analyses as well as logistic regression analyses were performed to
develop a model that identifies patients at risk for developing NOMI.
Results: Eight hundred sixty-five patients were included in the study, of whom 78 developed NOMI. Among
preoperative parameters, renal insufficiency, diuretic therapy, and age>70 years showed the highest odds ratios
for postoperative NOMI. The highest odds ratios for development of NOMI were observed with postoperative
variables. In particular, the need for intra-aortic balloon pump support and serum lactate concentrations>5
mmol/L proved to be serious risk factors. Using a linear discriminant analysis with 7 variables, 92.3% of pa-
tients were correctly classified (sensitivity 76.9%, specificity 93.8%).
Conclusions: A high index of suspicion for NOMI in patients with the above-mentioned risk factors may de-
crease the diagnostic and therapeutic delay. To identify at-risk patients the developed risk equation is a useful
tool with a high specificity. (J Thorac Cardiovasc Surg 2013;145:1603-10)P
MNon-occlusivemesenteric ischemia (NOMI) is a rare but se-
rious complication after cardiac surgery. NOMI was first
described by Ende in 19581 as summarizing all forms of
mesenteric ischemia without occlusion of the mesenteric ar-
teries. NOMI has been generally defined as ‘‘intestinal gan-
grene in the presence of a patent arterial tree.’’2 Although
incidence rates around 1% have been reported, mortality
is up to 90%.3,4
The exact pathophysiology of NOMI is currently not
fully understood; it is assumed that the key mechanism is
an extreme reduction or maldistribution of splanchnic blood
flow. Intestinal ischemia results in compromised integrity of
the mucosal layer with bacterial translocation, bacteremia,
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The Journal of Thoracic and CarThe clinical signs of NOMI—oliguria, increased serum
lactate levels, decreased oxygenation, or hypotension—
are unspecific. The same is true for abdominal pain, which
in addition may be suppressed by analgosedation.5,6
Angiography is currently the only means of establishing
the diagnosis; in addition it allows for intra-arterial applica-
tion of vasodilators as the specific treatment. Angiography,
however, is an invasive procedure that cannot be applied too
liberally. In addition, it must be instituted early enough to be
able to correct the vascular pathology. To minimize morbid-
ity and mortality due to NOMI, it is thus crucial to identify
patients who are at risk of developing this complication.7
A variety of risk factors have been proposed on the basis
of retrospective investigations of heterogeneous patient co-
horts. Among others, advanced age, renal failure, and dif-
ferent forms of shock as well as the use of an intra-aortic
balloon pump (IABP) have been found to be associated
with NOMI.3,4,7 At this time there is no prospective
identification of risk factors for NOMI.
Therefore, aim of this prospective study was to identify
perioperative risk factors for NOMI in a large cohort of pa-
tients undergoing elective cardiac surgery.METHODS
The study was designed as a prospective cohort study and approved by
the local ethics committee (Landes€arztekammer des Saarlandes; ID: 199/
09). From January 1, 2010, to March 31, 2011, all patients scheduled fordiovascular Surgery c Volume 145, Number 6 1603
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Mcardiac surgery at our institution were screened for participation in this
trial. The inclusion criterion was elective cardiac surgery with cardiopul-
monary bypass. Exclusion criteria were age<18 years, refusal to partici-
pate, planned off-pump surgery, urgent cardiac surgery, hemodynamic
instability with emergency indication for cardiac surgery, or insufficient
knowledge of the German language. Written informed consent was ob-
tained from all patientsmeeting the above-mentioned criteria. The patients’
demographic and perioperative data were entered in a computerized data
bank in addition to the medical record chart (see Appendix 1).
Radiographic Analysis
If NOMI was suspected arterial angiography was performed. The deci-
sion to perform angiography was based on the presence of at least 2 of 4
possible clinical indicators: new onset of oliguria (urine output<0.5 mL/
kg/hour for at least 6 hours) or anuria, abdominal distention with decreased
or absent bowel sounds, serum lactate levels>5.0 mmol/L or metabolic ac-
idosis (base excess<5mmol/L). In accordance to the definition of cardio-
genic shock,8 angiography was only performed in patients with a systolic
blood pressure>90 mm Hg, and a cardiac index>1.8 L/minute/m2.
The examinations were performed on an undercouch tube/overcouch
detector angiography unit (Axiom Artis, Siemens Medical Solutions, For-
chheim, Germany) with a maximum field of view of 40 cm.
In all cases the common femoral artery was accessed and a 6F sheath
was inserted. The superior mesenteric artery was intubated with a 4F cath-
eter (Cordis, Johnson & Johnson Medical Products GmbH, Vienna, Aus-
tria) with a cobra tip configuration and a digital subtraction angiography
was obtained by automatic contrast medium injection (contrast medium:
Imeron 300, Bracco, Milan, Italy).
All images were assessed by an experienced radiologist and an intensiv-
ist on a consensus basis. In accordance with our previously published scor-
ing system,9 NOMI was diagnosed whenever the total score was more than
1 (Table 1).
Statistics
Data analysis was performed using SPSS Statistics version 19 (IBM,
Ehningen, Germany). As a first step, patients with and without NOMI as
confirmed by angiography were compared with respect to all variables as-
sessed in this study (see Appendix 1). For categorical variables, c2 tests
were performed. For continuous variables the differences in manifestation
(expressed as mean  standard deviation) between NOMI and non-NOMI
patients were compared with Student t tests (Welch’s t tests in case of in-
homogeneous variance). As a second step, odds ratios were calculated
for all categorical dichotomized variables (with 95% confidence intervals)
to describe the risk of developing NOMI.
Previous risk analyses only pointed toward differences between NOMI
and non-NOMI patients regarding several variables. These analyses, how-
ever, did not exceed the description of the differences. Therefore, in a third
step, linear discriminant analyses as well as logistic regression analyses
were performed to develop a model that separates patients at high risk
for developing NOMI from patients at low risk. To derive a medically sen-
sitive predictivemodel, we stepwise excluded variables with low predictive
values: After exclusion of the variable with the lowest predictive value,
both linear discriminant and logistic regression analysis were calculated
again to see how the coefficient loadings changed. Subsequently, the vari-
able with the lowest predictive value by now was excluded, and analyses1604 The Journal of Thoracic and Cardiovascular Surwere iterated until the final equation was found. In addition, we partially
reincluded several variables to compare different possible predictive
models. This was done when variables had been excluded due to statistical
reasons, but were previously reported to influence NOMI.RESULTS
During the study period, 1163 adult patients underwent
elective cardiac surgery with extracorporeal circulation. Be-
cause 298 patients refused participation in the study the fi-
nal study population consisted of 865 individuals (74%).
Angiography was performed in 88 patients. Of these, 78 pa-
tients (9% of the total cohort) had the typical angiographic
signs of NOMI in the absence of cardiogenic shock. Ten ad-
ditional patients underwent angiography based on clinical
suspicion; their findings were unremarkable. At the time
of angiography systolic blood pressure was 120  15 mm
Hg, cardiac index was 2.7  0.3 L/minute/m2, and central
venous saturation was 69.1%  1.2%. Relevant outcome
data are shown in Table 2.
Patients with NOMI differed in many respects from pa-
tients without NOMI (Table 3). Among preoperative param-
eters, renal insufficiency, diuretic therapy, and age>70 years
showed the highest odds ratios for postoperative NOMI.
Intraoperative risk factors with clearly increased odds
ratios for postoperative NOMI were duration of operation
>240 minutes and cardiopulmonary bypass time >100
minutes.
The highest odds ratios for development of NOMI were
observed with postoperative variables. In particular, the
need for IABP support, levosimendan therapy, transfusion
of>1 unit packed red blood cells, and re-exploration for
bleeding proved to be serious risk factors. In addition, se-
rum lactate concentrations>5 mmol/L and norepinephrine
support>0.1 mg/kg/minute were associated with a clearly
increased risk to develop NOMI (Table 4).
Among the calculated models, the best classification
regarding medical sensitivity and practice orientation was
obtained by linear discriminant analysis. The final model
included 7 variables (see below; for standardized canonical
coefficients see Appendix 2). The discriminant function
was highly significant (Wilks’ L, 0.59; c27, 449.41;
P<.001). It was calculated with the following equation:
d ¼ 3:853 postoperative IABP support ð0 ¼ no; 1 ¼ yesÞ
þ 1:913 re exploration for bleeding ð0¼no; 1¼ yesÞ
þ 1:863 postoperative need for more than 1 unit PRBC
ð0 ¼ no; 1 ¼ yesÞ
þ 1:523 postoperative serum lactate level>5 mmol=l
ð0 ¼ no; 1 ¼ yesÞgery c June 2013
TABLE 1. Specific nonocclusive mesenteric ischemia (NOMI) score system9
Criteria/score Description
Vessel morphhology 0: None SMA trunk, branches, and mesenteric arcades normal
1: Mild SMA trunk normal, several SMA branches and/or mesenteric arcades slightly
constricted
SMA trunk slightly constricted, normal SMA branches and mesenteric arcades
SMA trunk, several SMA branches and/or mesenteric arcades slightly constricted
2: Moderate SMA trunk, multiple SMA branches, and/or mesenteric arcades constricted
3: Severe SMA trunk, multiple SMA branches, and/or mesenteric arcades constricted
Contrast medium reflux into the aorta 0: None No contrast medium reflux into the aorta
1: Mild Some contrast medium reflux into the aorta
2: Severe Severe contrast medium reflux with complete aortogram
Contrasting of the parenchyma 0: Complete Homogeneous contrasting of the intestine
1: Some deficiency Inhomogeneous contrasting of the intestine
2: Complete deficiency No contrasting of the intestine
Distension of the intestine 0: None Up to 3 air containing, distended bowel loops
1: Mild >3 air containing, distended bowel loops
2: Severe Ubiquitary distended bowel loops
Contrasting time of portal vein 0: Normal <8 sec
1: Slightly delayed 9-12 sec
2: Delayed >13 sec
Total score No 0
Mild (Grade 1) 1-5
Moderate (Grade 2) 6-7
Severe (Grade 3) 8-11
Summary of a specific NOMI score system used for image analysis with respect to vessel morphology, contrast medium reflux into the aorta, contrast enhancement and distension
sults into a total score. SMA, Superior mesenteric artery.
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Mþ 1:073 postoperative levosimendan therapy
ð0 ¼ no; 1 ¼ yesÞ
þ 0:773 postoperative need for norepinephrine
>0:1 mg=kg=min
ð0 ¼ no; 1 ¼ yesÞ
þ 0:363 postoperative loss of sinus rhythm
ð0 ¼ no; 1 ¼ yesÞ
 0:32 ðconstant of the equationÞ
of the intestine, as well as the time of portal vein filling. The sum of each category reTABLE 2. Comparison of relevant outcome data
Outcome NOMI (n ¼ 78)
Non-NOMI
(n ¼ 787) P value
Mechanical ventilation (h) 166.5  23.3 22.1  2.0 <.001
Renal replacement therapy (%) 42 (53.4) 17 (2.2) <.001
LOS ICU (d) 9.3  1.1 1.8  0.1 <.001
LOS IMC (d) 6.1  0.7 2.2  0.1 <.001
LOS hospital (d) 20.2  1.5 11.8  0.2 <.001
30-day mortality (%) 17 (22.2) 10 (1.2) <.001
Data are expressed as n (%) or mean  standard deviation. Boldface indicates statis-
tically significant P values.NOMI,Nonocclusivemesenteric ischemia; LOS, length of
stay; ICU, intensive care unit; IMC, intermediate care unit.
The Journal of Thoracic and CarThe discrimination value was 1.18; individuals scoring
higher were suspected to experience NOMI. With our
model we could account for 40.7% of the variance.
In total, 92.3% of patients were correctly classified as
patients with or without NOMI (Table 5). The rate of
correct prediction was 76.9% for patients with NOMI
(sensitivity), and 93.8% for patients without NOMI
(specificity).
A parallel logistic regression model with the same inde-
pendent variables as used in the prior model could ac-
count for 50.1% of variance (Nagelkerke R2, 0.50;
model c2, 223.26; P<.001) and allowed for 93.9% cor-
rect predictions (Table 5). The regression model was infe-
rior in terms of sensitivity (43.6%) but superior in
specificity (98.9%) to the model derived from linear dis-
criminant analyses. Importantly, 44 patients with NOMI
had been mistakenly classified as asymptomatic using
the regression equation, whereas the same applied for
only 18 patients using the equation obtained through dis-
criminant analyses.DISCUSSION
A life-threatening complication of cardiac surgical proce-
dures is intestinal ischemia.3,4 The pathomechanism of
NOMI is not well understood. It is known that ileum
and distal jejunum are most severely affected.7 It is as
yet unclear if NOMI is simply the delayed result ofdiovascular Surgery c Volume 145, Number 6 1605
TABLE 3. Summary of statistically significant differences between patients with and without nonocclusive mesenteric ischemia (NOMI)
Risk factor NOMI (n ¼ 78) Non-NOMI (n ¼ 787) P value
Demographics Age (y) 72.0  1.0 62.8  0.5 <.001
Height (cm) 169.0  1.1 172.3  0.3 .002
EuroSCORE 8.6  0.4 5.8  0.1 <.001
Comorbidity Atrial fibrillation (%) 20 (26) 115 (14) .009
Coronary artery disease (%) 48 (62) 325 (41) <.001
Pulmonary hypertension (%) 31 (40) 174 (22) <.001
Chronic obstructive pulmonary disease (%) 11 (14) 53 (7) .02
Renal insufficiency (%) 15 (19) 48 (6) <.001
Status past stroke (%) 7 (9) 28 (4) .02
Medication Diuretic (%) 58 (74) 346 (44) <.001
Phenprocoumon (%) 13 (17) 68 (9) .02
Statin (%) 34 (44) 232 (30) .01
Intraoperative Coronary artery bypass grafting operations 42 (54) 285 (36) .002
Operation time (min) 215.6  8.4 166.7  1.9 <.001
Cardiopulmonary bypass time (min) 114.0  6.4 82.8  1.2 <.001
Crossclamp time (min) 71.6  4.3 54.4  0.8 <.001
Postoperative Intra-aortic balloon pump support (%) 13 (17) 1 (0.1) <.001
Sinus rhythm (%) 14 (18) 365 (46) <.001
Blood loss (ml) 1116.1  96.7 622.2  17.5 <.001
Re-exploration for bleeding (%) 18 (23) 13 (2) <.001
Packed red blood cells (n) 3.1  0.2 1.7  0.1 <.001
Levosimendan therapy (%) 7 (9) 4 (0.5) <.001
Norepinephrine (mg/kg/min) 0.26  0.03 0.06  0.01 <.001
Serum lactate>10 mmol/L 11 (14) 2 (0.3) <.001
Serum lactate>5 mmol/L 28 (36) 29 (4) <.001
Base excess<5 39 (50) 124 (16) <.001
pH<7.2 2 (3) 6 (0.8) <.001
Urine output within first 24 h (mL) 2151  163 2698  59 .002
Urine output within first 24 h (mL/kg/h) 1.13  0.08 1.41  0.03 .002
Data are expressed as n (%) or mean  standard deviation. Boldface indicates statistically significant P values. EuroSCORE, European System for Cardiac Operative Risk
Evaluation.
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Mmicrocirculatory alterations initiated during cardiopulmonary
bypass (CPB) or rather themanifestation of a separate disease.
Several studies have also documented alterations in intestinal
microcirculation during CPB.10-13 Impaired intestinal blood
flowmay result in breakdown of the intestinal barrier,14which
contributes to further aggravation of the physiologic alter-
ations after CPB. Alternatively, it may be assumed that the
changes in themicrocirculation are a consequence of thevaso-
pressor treatment that is necessary inmany patients during and
after operations involving CPB.15
NOMI is a difficult clinical problem due to the nonspe-
cific nature of the symptoms and difficulty in diagnosis.
Early identification of patients at highest risk will allow
lowering the threshold for angiography as the essential di-
agnostic and therapeutic tool. Therefore, we initiated this
prospective study to identify isolated risk factors and
patients at risk for NOMI.
Previous studies have identified advanced age, severe
heart failure, cardiogenic shock, chronic renal failure, and
diuretic medication as important preoperative risk factors
for the development of mesenteric ischemia.7,16 Among
these, advanced age (>70 years), chronic renal failure,1606 The Journal of Thoracic and Cardiovascular Surand diuretic medication increases the odds ratio to
develop NOMI in our study between 3- and 4-fold. These
risk factors alone do not provide conclusive evidence, but
may be indicative for the susceptibility of patients to devel-
opment NOMI.
The most prominent postoperative factors described in
the literature are hypovolemic shock, cardiogenic shock, ad-
ministration ofa-adrenergic drugs, or the use of an IABP.7,16
In line with these findings, extended norepinephrine use,
levosimendan therapy, or postoperative IABP support
increases the odds ratio to develop NOMI in our study
between 18- and 153-fold.
Vasopressor treatment is necessary in many patients
during and after operations involving CPB.17-19 In this
context, treatment with a-adrenergic catecholamines like
norepinephrine may lead to an increased incidence of
NOMI after CPB.12 It may be assumed that these changes
in the microcirculation are a consequence of a hypercon-
tractile response of ileal microvessels after a-adrenoceptor
stimulation.12,15,17 In addition, norepinephrine simulates
in a dose-dependent manner b receptors, which has been
shown to increase intestinal oxygen consumption.20gery c June 2013
TABLE 4. Odds ratios of perioperative risk factors
Risk factor
Odds
ratio 95% CI
P
value
Demographics Age>70 y 2.82 1.74-4.60 <.001
Height>170 cm 0.51 0.32-0.82 <.05
EuroSCORE>7 2.33 1.65-4.01 <.001
Atrial fibrillation 2.17 1.27-3.73 <.001
Comorbidity Coronary artery disease 2.03 1.31-3.32 <.05
Pulmonary hypertension 2.48 1.53-4.01 <.001
Chronic obstructive
pulmonary disease
2.46 1.22-4.95 <.001
Renal insufficiency 3.95 2.12-7.37 <.001
Status past stroke 2.60 1.10-6.16 <.001
Medication Diuretics 3.79 2.24-6.43 <.001
Phenprocoumon 2.12 1.11-4.03 <.05
Statins 1.85 1.15-2.97 <.05
Intraoperative Coronary artery bypass
grafting operations
2.01 1.29-3.28 <.05
Operation time>240 min 5.62 3.26-9.69 <.001
Operation time>180 min 3.28 2.02-5.31 <.001
Cardiopulmonary bypass
time>100 min
3.83 2.38-6.17 <.001
Crossclamp time>60 min 2.19 1.37-3.49 <.05
Postoperative Intra-aortic balloon pump
support
153.00 19.70-1188.08<.001
Loss of sinus rhythm 3.53 2.00-6.22 <.001
Blood loss>1000 ml 7.22 4.29-12.14 <.001
Re-exploration for bleeding 24.22 11.64-59.42 <.001
Packed red blood cells>2 20.05 11.39-35.27 <.001
Packed red blood cells>1 12.77 7.66-21.27 <.001
Levosimendan therapy 18.78 5.37-65.71 <.001
Norepinephrine
>0.2 mg/kg/min
17.47 9.01-33.88 <.001
Norepinephrine
>0.1 mg/kg/min
12.14 7.18-20.52 <.001
Serum lactate>10 mmol/L 139.09 17.81-1086.33<.001
Serum lactate>5 mmol/L 15.60 8.61-28.26 <.001
Base excess<5 5.50 3.39-8.93 <.001
pH<7.2 3.33 0.66-16.80 <.001
Oliguria/anuria within the
first 24 h
2.17 1.22-3.65 <.001
Data are expressed as odds ratio for each recorded categorical respectively dichoto-
mized variable and 95% confidence interval (CI). Boldface indicates statistically sig-
nificant P values. EuroSCORE, European System for Cardiac Operative Risk
Evaluation.
TABLE 5. Comparison between linear discriminant and logistic
regression analysis to predict nonocclusive mesenteric ischemia
(NOMI)
Clinical
diagnosis
Predicted diagnosis
Linear discriminant
analysis
Logistic regression
analysis
non-NOMI NOMI non-NOMI NOMI
non-NOMI 738 (93.8) 49 (6.2) 778 (98.9) 9 (1.1)
NOMI 18 (23.1) 60 (76.9) 44 (56.4) 34 (43.6)
Data are presented as n (%). Boldface indicates correct predictions. Linear discrim-
inant analysis classified 92.3% of all patients correctly, whereas logistic regression
analysis showed a correct prediction rate of 93.9% (n ¼ 865).
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MIrrespective of the surgical procedure, patients after car-
diac surgery are still vulnerable to low cardiac output syn-
drome or cardiogenic shock. Pharmacologic interventions
are commonly limited to catecholamines, phosphodiester-
ase III inhibitors, and levosimendan, which has recently re-
ceived more attention.21 Due to the cost of levosimendan it
is usually restricted to refractory cardiogenic shock. Al-
though levosimendan therapy is well tolerated, most of its
adverse effects are due to its vasodilating effect.21 This
side effect itself and/or the resulting need for increased va-
sopressor treatment may additionally aggravate intestinalThe Journal of Thoracic and Carhypoperfusion. Nevertheless, we do not think that levosi-
mendan itself is a risk factor for the development of
NOMI, but its need in the treatment of cardiogenic shock
seems to be a clue for impaired intestinal perfusion.
IABP implantation after cardiac surgery is a commonly
used form of circulatory support for patients with postoper-
ative low cardiac output syndrome. Despite improving coro-
nary perfusion and reducing left ventricular afterload, IABP
use is known as risk factor for the development of lethal mes-
enteric ischemia.22 One explanation for this unwanted side
effect is the malposition of the IABP balloon, resulting in
compromised visceral blood flow. This hypothesis is sup-
ported by Rastan and colleagues23 who found a malposition
of the IABP balloon with consecutive visceral artery com-
promise in up to 97% of their study patients. After insertion
of the IABP, the position was immediately confirmed by
chest x-ray film. At angiography we only found 3 patients
(23%) with a malposition of the IABP balloon, which was
then corrected. Therefore, an incorrect-positioned IABP bal-
loon may aggravate a state of intestinal hypoperfusion, but
does not explain alone the>150-fold odds increase for the
development of NOMI in our patients. Moreover, NOMI
was confirmed after restoration of an adequate hemody-
namic, underlining that NOMI is a distinct complication
after cardiogenic shock. Therefore, despite an apparently
re-established stable hemodynamic situation, NOMI should
be kept in mind as a life-threatening complication.
Intestinal ischemiamay lead to a systemic inflammatory re-
sponse syndrome and sepsis thereby altering the coagulation
system in both ways, hyper- and hypocoagulation.24 Bleeding
is additionally known to be a strong proinflammatory stimu-
lus, which further aggravates systemic inflammatory response
syndrome and sepsis.24 A circulus vitiosus that ends up in dis-
tinct NOMI may be the result. This is supported by higher
odds ratios to develop NOMI in patients with increased blood
loss, need for>1 unit packed red blood cells, or need for chest
re-exploration. In 15 of 18 patients, however, no surgical
source of bleeding was found while re-exploring the chest,
suggesting coagulopathy caused by NOMI.
Elevated serum lactate levels, metabolic acidosis, and in-
creased serum creatinine kinase levels have been describeddiovascular Surgery c Volume 145, Number 6 1607
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Min previous studies to be indicative but not providing con-
clusive evidence for NOMI.4 We found significantly higher
serum lactate levels in patients with NOMI compared with
patients without. Furthermore, patients with serum lactate
levels of>5 mmol/L had an increased odds ratio of 15.60
to show the angiographic signs of NOMI. This may be
due to an increased intestinal lactate production as a result
of anaerobic glycolysis. It is, however, impossible to dis-
criminate between lactate production due to systemic or
local hypoperfusion.
All these postoperative predictors have to be looked at in
the context of preoperative morbidity and intraoperative
events. Especially intraoperative physiology is difficult or
impossible to define clearly; myocardial protection, subop-
timal correction of cardiovascular pathology, and hemody-
namic derangement cannot be quantified in clinical practice
and may have effects that extend into postoperative
treatment.
Despite the possibility to detect intestinal malperfusion
by contrast multidetector row computed tomography,25
catheter angiography remains the gold standard for the early
diagnosis of NOMI. In addition to the direct visualization of
the mesenteric blood flow, the inserted catheter allows se-
lective mesenteric intra-arterial infusion of vasodilatative
drugs. Early recognition and correction of the vascular pa-
thology is the only way to reduce the high morbidity and
mortality of NOMI.7 Nevertheless, angiography is an inva-
sive procedure that cannot be applied too liberally due to its
potential side effects. To alleviate the decision process to
perform angiography, we tried to identify patients who are
at risk to develop NOMI by using a discriminant and regres-
sion approach, respectively. The final risk equation showed
a good sensitivity and high specificity. Using this equation,
we were able to exclude NOMI in>90% of cases. As a re-
sult the sensitivity was only 76%; this reflects our key inten-
tion to aim for a high specificity. In our mind the high
mortality of untreated NOMI warrants a test that has the
lowest possible false negative rate.
Linear discriminant analysis may be discussed controver-
sially because this method is meant for the analysis of con-
tinuous independent variables. The use of supplemental
categorical variables, in the form of dummy variables, is al-
lowed. In our predictive model all continuous variables had
to be eliminated because they showed no explanatory value.
Because discriminant analysis is not designated for exclu-
sively dichotomous data, our equation model may be prob-
lematic for statistical reasons. From a clinical perspective,
the results obtained through linear discriminant analysis
are superior to the results obtained through logistic regres-
sion analysis. In the first case, the predictive model had
a false negative rate of 23.1% (n ¼ 18 [2.1% of the total
cohort]), whereas the predictivemodel derived from logistic
regression analysis had a rate of 56.4% (n ¼ 44 [5.1% of
the total cohort]). Because false negative NOMI predictions1608 The Journal of Thoracic and Cardiovascular Surare associated with high mortality rates, type II error is
much more important than sensitivity rate.
Another limitation of our study is that our control group
(non-NOMI patients) did not undergo angiography. There-
fore we cannot exclude that patients with clinical unappar-
ent forms of NOMI were missed. The mortality in our
control group was low (1.2%); in addition, none of these pa-
tients died within the first 10 postoperative days. These facts
and the clinical course of the patients makes NOMI very
unlikely.
Emergency operations are associated with a higher inci-
dence of NOMI.26 Due to the study design we excluded all
urgent and emergency operations. Therefore, we cannot
comment on whether or not these patients are at higher
risk for the development of NOMI. Nevertheless, our risk
equation consists of pre- and postoperative variables, which
helps to easily identify risk patients independent of the
operation indication.CONCLUSIONS
Our study provides for the first time prospective observa-
tional data on risk factors for the development of NOMI in
patients undergoing elective cardiac surgery. Summarizing
our results, a high index of suspicion for NOMI in patients
with the above-mentioned risk factors may decrease the di-
agnostic delay. This may lead to a decreased mortality due
to earlier intervention. To better identify risk patients the
developed risk equation is a useful tool with a high specific-
ity and low type II error rate.
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patient
patient
ented in years (y)
ht, documented in kilograms
ented in centimeters
E, documented in absolute value
ction, documented in percent (%)
eart Association functional class, documented in absolute value
d sinus rhythm at the day of admission to the hospital
erial pressure>140 mm Hg and/or diastolic arterial pressure>90 mm Hg
Index, documented in absolute value
ker at the day of admission to the hospital
years ¼ packs smoked/d 3 years as a smoker
by cardiac catheter examination
f valvular disease with indication for surgery
by angiography
onary artery pressure>25 mm Hg at rest or>30 mm Hg with exercise
iative for Chronic Obstructive Lung Disease 2
lomerular filtration rate<60 mL/min
nal failure with the need for dialysis
f malignant disease
stroke with or without residua
f beta blocker therapy for at least 4 wk before operation
f ACE inhibitor therapy for at least 4 wk before operation
f AT-1 blocker therapy for at least 4 wk before operation
f calcium antagonist therapy for at least 4 wk before operation
f diuretic therapy for at least 4 wk before operation
f acetylsalicylic acid therapy for at least 4 wk before operation
f phenprocoumon therapy for at least 4 wk before operation
f amiodarone therapy for at least 4 wk before operation
f statin therapy for at least 4 wk before operation
(Continued)
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APPENDIX 1. Continued
Data Description
Intraoperative Procedure type
CABG operations All kinds of coronary artery bypass surgery with cardiopulmonary bypass
Valve operations All kinds of valve surgery with cardiopulmonary bypass
Pulmonary thromboendarterectomy Pulmonary thromboendarterectomy
Combination surgery All kinds of combination surgery with cardiopulmonary bypass
Redo CABG and/or valve All kinds of redo surgery with cardiopulmonary bypass
Operation time Operation time, documented in minutes
CPB time Cardiopulmonary bypass time, documented in minutes
Crossclamp time Aortic crossclamp time, documented in minutes
HCA time HCA time, documented in minutes
Postoperative IABP support Postoperative need for IABP support
Loss of sinus rhythm Documented loss of sinus rhythm for at least 6 h
Blood loss Blood loss, documented in milliliters
Re-exploration for bleeding Need for re-exploration of the chest due to bleeding
Packed red blood cells No. of packed red blood cells
Levosimendan therapy Postoperative need for levosimendan therapy
Norepinephrine therapy Postoperative need for norepinephrine therapy, documented in micrograms/kilogram/
minute
Serum lactate Postoperative serum lactate levels
Base excess Postoperative base excess values
pH value Postoperative pH values
Urine output within first 24 h Postoperative urine output, documented in milliliters
Urine output within first 24 h (ml/kg/h) Postoperative urine output, documented in milliliters/kilogram/hour
Outcome Mechanical ventilation Time of postoperative mechanical ventilation, documented in hours
Renal replacement therapy Need for renal replacement therapy due to new onset of acute kidney injury
LOS ICU LOS in the ICU, documented in days
LOS IMC LOS in the IMC unit, documented in days
LOS hospital LOS in the hospital, documented in days
30-d mortality 30-d mortality including all causes of death
In total 52 isolated risk factors where included in our risk stratification calculations. ACE, Angiotensin-converting enzyme; AT-1, angiontensin-1; CABG, coronary artery bypass
grafting; CPB, cardiopulmonary bypass; HCA, hypothermic circulatory arrest; IABP, intra-aortic balloon pump; LOS, length of stay; ICU, intensive care unit; IMC, intermediate
care unit; EuroSCORE, European System for Cardiac Operative Risk Evaluation.
APPENDIX 2. Summary of stepwise discriminant analysis
Predictor
Standardized
coefficient loadings
Postoperative IABP support 0.451
Re-exploration for bleeding 0.348
Postoperative need for more than 2 PRBC 0.456
Postoperative serum lactate level>5 mmol/L 0.351
Postoperative need for norepinephrine
>0.1 mg/kg/min
0.221
Postoperative levosimendan therapy 0.117
Postoperative loss of sinus rhythm 0.179
Canonical correlation 0.638
Eigenvalue 0.687
Wilks’ lambda 0.593
c2 449.41 (df ¼ 7; P<.001)
IABP, Intra-aortic balloon pump; PBRC, packed red blood cells; df, degrees of
freedom.
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